Adia Nutrition Paves Way for Nasdaq and New Investors Through SEC Form 10 Submission
Rhea-AI Summary
Adia Nutrition (OTCQB: ADIA) has engaged an independent accounting firm and securities counsel to prepare and file a Form 10 with the U.S. SEC, marking a move from OTC reporting to full SEC reporting.
The company expects to submit the Form 10 by end of November 2025, notes an SEC review/recognition period of 60 days, and anticipates the filing becoming effective by late January 2026. Full reporting will require audited financials, regular disclosures, and enhanced governance and is presented as a step toward meeting Nasdaq listing requirements and attracting institutional and accredited investors.
Positive
- Planned Form 10 submission by end of November 2025
- SEC review/recognition period specified as 60 days
- Anticipated Form 10 effectiveness by late January 2026
- Positions company to pursue Nasdaq listing
- Full SEC reporting enables access to institutional investors
Negative
- Full SEC reporting requires comprehensive audited financials
- Transition entails enhanced governance and disclosure obligations
- Company must complete audits and documentation before submission
News Market Reaction – ADIA
On the day this news was published, ADIA declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Winter Park, Florida--(Newsfile Corp. - October 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is thrilled to announce a major milestone in its growth journey. The Company has engaged an independent public accounting firm and securities counsel to prepare and file its Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC). This filing marks a significant step beyond OTC reporting and positions Adia as a fully reporting public company under the Securities Exchange Act of 1934, a critical move that enhances transparency, credibility, and access to the broader capital markets. Unlike OTC reporting, which provides limited disclosure, full SEC reporting requires comprehensive audited financials, regular operational updates, and robust corporate governance, all of which unlock new opportunities for growth and investment.
Adia expects to submit the Form 10 by the end of November 2025, with the SEC review and recognition period set at 60 days. Based on this timeline, the filing is anticipated to become fully effective by late January 2026. This advancement is also a key step toward meeting Nasdaq listing requirements, bringing Adia closer to joining one of the world's most prestigious stock exchanges and attracting a new class of institutional and accredited investors.
"Filing the Form 10 is a transformative moment for Adia Nutrition," said Larry Powalisz, CEO of Adia Nutrition Inc. "Transitioning from OTC reporting to full SEC compliance elevates our visibility and credibility, opens doors to sophisticated investors, and sets the stage for strategic growth opportunities as we continue expanding our leadership in regenerative medicine, advanced biologics, and clinical services nationwide."
With full SEC reporting status, Adia expects to attract institutional investors, mutual funds, and accredited investors who typically only invest in fully reporting companies. The increased transparency and regulatory compliance will also enable strategic partnerships and broader market recognition, fueling the next stage of Adia's rapid expansion. The Company's accounting and legal teams are finalizing documentation and audits to ensure a smooth submission, and shareholders can expect regular updates as the filing and SEC recognition process progresses.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270232
FAQ
When will Adia Nutrition (ADIA) file its Form 10 with the SEC?
How long is the SEC review period for Adia Nutrition's Form 10 (ADIA)?
When could Adia Nutrition (ADIA) become a fully reporting SEC company?
Does filing Form 10 help Adia Nutrition (ADIA) list on Nasdaq?
What does full SEC reporting require for Adia Nutrition (ADIA)?
Will Adia Nutrition (ADIA) attract institutional investors after Form 10?
How can investors or partners contact Adia Nutrition about ADIA updates or licensing?
